At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 116 enrolled
Drug / intervention
Posaconazole +1 moredrug
Likely dose
Posaconazole 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection
In Brief
A Phase 3 clinical trial evaluating Posaconazole and Voriconazole for Aspergillosis. Completed, enrolled 116 participants.
Detailed Summary
The primary objective of this study is to assess and compare the safety of posaconazole with voriconazole in Japanese participants with aspergillosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAspergillosis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartJul 2014
Primary CompletionJan 2018
TodayJul 2026
First PostedJul 2, 2014
Enrollment StartJul 29, 2014
Primary CompletionJan 24, 2018
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12 years ago
Interventions
Posaconazoledrug
300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
Voriconazoledrug
300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days